KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Before 2027 35%-1.0ptLíder entre 3 opciones
Calidad del mercado
42 / 100
Baja calidadVolumen 24h
1,9 €
Liquidez
29,6 mil €
Alta liquidezSpread
8.0 pt
Spread amplioDatos de mercado
Actualizado hace 4 minutos
24 mar 26, 14:00 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
FDA moves BPC-157 to Category 1 by which date?
PolymarketHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWill we get AGI before 2027?
Manifold MarketsFDA approves skin cancer vaccine by which date?
PolymarketMeasles cases in 2026?
KalshiReglas
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
Liquida mediante:Food and Drug Administration
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
Mercados abiertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volumen total
- 15,6 M €
- Volumen 24h
- 30,4 mil €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volumen total
- 652,8 mil €
- Volumen 24h
- 3,5 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes-0.7pt3%
- Volumen total
- 1,6 M €
- Volumen 24h
- 2,9 mil €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt97%
- Above 600059%
+2 resultados más
- Volumen total
- 865,3 mil €
- Volumen 24h
- 2,7 mil €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volumen total
- 915,3 mil €
- Volumen 24h
- 1,4 mil €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+1.0pt65%
- September41%
- June28%
- Volumen total
- 84 mil €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de When will the FDA reclassify BPC-157 to Category 1??
- Kalshi cotiza Before 2027 al 35% a fecha de 9 de septiembre de 2026.
- ¿Cuándo se resuelve When will the FDA reclassify BPC-157 to Category 1??
- Está previsto que When will the FDA reclassify BPC-157 to Category 1? se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida When will the FDA reclassify BPC-157 to Category 1??
- Kalshi liquida este mercado del siguiente modo: If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.